The November 2015 GEN magazine article "Cell-Free DNA Prospecting Starts to Pan Out" by Lisa Heiden, Ph.D. looks at the applications of cell-free DNA (cfDNA) -based diagnostics that are considered to be on the verge of entering the clinical mainstream.
Read MoreBiological Dynamics Inc., a privately held molecular diagnostics company and a pioneer in the field of Alternating Current Electrokinetics (ACE) - based diagnostics, announces the appointment of Paul Richard Billings, MD, PhD, FACP, FACMG to the Company’s Board of Directors.
Read MoreBiological Dynamics, Inc., a molecular diagnostics company, announced today that it has completed a $26.8M round of financing.
Read MoreBiological Dynamics CEO, Raj Krishnan, Phd, introduced "Quantification of Circulating Biomarkers from Plasma and Serum Using AC Electrokinetic" presentation at the 7th Annual Next Generation Diagnostics Summit at Washington, DC.
Read MoreSAN DIEGO, Calif., April 6, 2015 -- Biological Dynamics, Inc. today announced that, David Charlot, PhD, President and CTO, will present at the 2nd Annual Molecular Diagnostics Europe Conference on Thursday, April 16 at 10:05PM in Lisbon, Portugal.
Read MoreSAN DIEGO, Calif., January 6, 2015 -- Biological Dynamics, Inc. today announced that Raj Krishnan, PhD and David Charlot, PhD, President and CTO, will present at this annual investor and partnering conference on Monday, January, 12, 2015 in San Francisco, CA.
Read MoreBiological Dynamics is a private molecular diagnostics company located in San Diego. Our proprietary technology offers a novel, fast, and cost-effective lab-on-chip ACE platform that isolates nanoparticles from high conductance physiological solutions.
Our product, the TR(ACE)™ assay, will utilize the platform for monitoring treatment response in oncology. TR(ACE)™ has not been cleared or approved by the U.S. FDA or any foreign regulatory agency.
